Harrow (HROW) Competitors

Nuvalent (NASDAQ:NUVL) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Do institutionals and insiders have more ownership in NUVL or HROW?

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 10.2% of Nuvalent shares are held by company insiders. Comparatively, 15.2% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts recommend NUVL or HROW?

Nuvalent presently has a consensus target price of $118.91, suggesting a potential upside of 56.19%. Harrow has a consensus target price of $64.67, suggesting a potential upside of 64.22%. Given Harrow's stronger consensus rating and higher probable upside, analysts plainly believe Harrow is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	3.08
Harrow	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Is NUVL or HROW more profitable?

Nuvalent has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-32.58%	-30.14%
Harrow	-4.49%	-2.18%	-0.35%

Which has preferable earnings and valuation, NUVL or HROW?

Harrow has higher revenue and earnings than Nuvalent. Harrow is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$260.76M	-$4.90	-15.54
Harrow	$199.61M	7.30	-$17.48M	-$0.25	-157.51

Which has more volatility & risk, NUVL or HROW?

Nuvalent has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Does the media prefer NUVL or HROW?

In the previous week, Harrow had 19 more articles in the media than Nuvalent. MarketBeat recorded 30 mentions for Harrow and 11 mentions for Nuvalent. Harrow's average media sentiment score of 0.96 beat Nuvalent's score of 0.83 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harrow beats Nuvalent on 10 of the 15 factors compared between the two stocks.